Ask AI
ProCE Banner Activity

Do It Better: Special Considerations for Managing Cardio–Renal–Metabolic Disease With SGLT2 Inhibitors

Clinical Thought

Learn about specific considerations for using SGLT2 inhibitors in treatment plans for patients with cardio–renal–metabolic disease, such as managing hypotension among those with heart failure with preserved ejection fraction and addressing amputation risk among patients with pulmonary arterial disease.

Released: December 01, 2025

Continue Activity View Activity

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company.

Boehringer Ingelheim Pharmaceuticals, Inc.

Eli Lilly and Company

Target Audience

This program is intended for primary care physicians, nurse practitioners, and physician associates who care for patients with cardio-renal-metabolic conditions.

Program Learning Goal

The goal of this activity is to improve knowledge, competence, and performance of primary care physicians, nurse practitioners, and physician associates to optimize treatment for patients with cardio-renal-metabolic conditions.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Detail the unmet needs of patients with cardio-renal-metabolic diseases and the importance of timely recognition and intervention

  • Incorporate recent evidence regarding the benefits and safety considerations of early and ongoing use of SGLT2 inhibitors into treatment decisions for patients with cardio-renal-metabolic diseases

  • Leverage current guidelines when managing patients with cardio-renal-metabolic comorbidities, including type 2 diabetes, heart failure, and chronic kidney disease

Faculty Disclosure

Primary Author

Jennifer B. Green, MD: consultant/advisor/speaker: AstraZeneca, Bayer, Boehringer Ingelheim, Corcept, Lilly, Merck, Mineralys, NovoNordisk, Valo, Vertex, Zealand; researcher: Bluedrop, Boehringer Ingelheim, COUR, Gentibio, Lilly, Merck, Roche.

Michelle Kittleson, MD, PhD, has no relevant financial relationships to disclose.

Jay H. Shubrook, DO, FACOFP, FAAFP: consultant/advisor/speaker: Abbott, Bayer, Corcept, Insulet, Lilly, Madrigal, Novo Nordisk, Sanofi.